ABSTRACT
OBJECTIVE: To assess whether the retention rate of certolizumab pegol (CZP) was longer than that of other tumour necrosis factor inhibitors (TNFi) based on baseline rheumatoid factor (RF) levels. METHODS: Longitudinal, retrospective and multicentre study including patients with RA who were treated with any TNFi (monoclonal antibodies (mAB), etanercept (ETA) or CZP). Log-rank test and Cox regressions were conducted to evaluate the retention rate in the three groups according to the level of RF, with the third quartile of the baseline levels used as cut-off: <200 (Subject(s)
Arthritis, Rheumatoid
, Tumor Necrosis Factor Inhibitors
, Humans
, Retrospective Studies
, Tumor Necrosis Factor Inhibitors/therapeutic use
, Rheumatoid Factor
, Treatment Outcome
, Arthritis, Rheumatoid/drug therapy
, Certolizumab Pegol/therapeutic use
, Etanercept/therapeutic use
, Antibodies, Monoclonal/therapeutic use
